fbpx

QQQ
+ 0.00
373.83
+ 0%
BTC/USD
-3961.81
43776.01
-8.3%
DIA
+ 0.05
345.59
+ 0.01%
SPY
+ -0.01
441.41
+ 0%
TLT
+ 0.00
149.17
+ 0%
GLD
+ 0.01
163.76
+ 0.01%

Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know

July 7, 2021 3:02 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know

Biohaven Pharmaceutical Ltd. (NYSE:BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday.

What Happened: Nurtec achieved preliminary net product revenue of approximately $93 million in the second quarter, according to the company.

Since its launch in March 2020, Nurtec ODT has earned around $200 million in revenue, with over 750,000 prescriptions filled across 38,000 prescribers, CEO Vlad Coric said in a statement. 

Why It's Important: These results continue to exceed expectations for the drug and demonstrate the profound impact Nurtec is having on patients suffering from migraines, Coric said.

The second quarter saw robust growth in terms of sales after Biohaven received FDA approval for migraine prevention in the last few weeks, according to the release.

Consensus estimates of $59 million in second-quarter sales were shattered by the report, SVB Leerink analyst Marc Goodman said in a note. 

What's Next: "The market appears to have been expecting good numbers, as the stock has been strong lately even before the ~10% additional increase today on this news," the analyst said.

Going forward, potential changes to Nurtec's gross-to-net run rate should be something for investors keep an eye on, he said. 

BHVN Price Action: Shares of Biohaven were up 12.34% to $111.05 at last check Wednesday. 

See also: BVHN Analyst Ratings

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

UPDATE: Mizuho On Biohaven Pharmaceutical Price Target Raise: Firm Cites Management Confidence In Further Nurtect ODT Results & Highlights Secured Commercial Coverage Following First Year Of Launch With Market Share Gain Relative To AbbVie's Ubrelvy

10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades

10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades

Canaccord Genuity On Biohaven Pharmaceutical Notes Co's Migraine-Related Catalysts', which could come at anytime in 1Q20 are: 1) a potential approval for the acute treatment of migraine; and 2)Phase 3 data for migraine prevention'

Canaccord Genuity Reiterates Buy, $80 Target On Biohaven Pharmaceutical Notes 'Pullback on generalized anxiety means opportunity before migraine-related catalysts'